您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报(医学版) ›› 2010, Vol. 48 ›› Issue (8): 103-106.

• 论文 • 上一篇    下一篇

异甘草酸镁治疗伴高胆红素血症病毒性肝炎的疗效观察

郭堑,农村立   

  1. 广西医科大学第四附属医院感染科, 广西  柳州 545005
  • 收稿日期:2010-04-16 出版日期:2010-08-16 发布日期:2010-08-16
  • 作者简介:郭堑(1970- ),女,副主任医师,主要从事病毒性肝炎的临床诊治研究。 E-mail:zggxlzgq@yahoo.com.cn

Clinical efficacy of magnesium isoglycyrrhizinate in the management of virus hepatitis with hyperbilirubinemia

GUO Qian, NONG Cun-li   

  1. Department of Infectious Diseases, the Fourth Affiliated Hospital of Guangxi Medical University, 
    Liuzhou 545005, Guangxi, China
  • Received:2010-04-16 Online:2010-08-16 Published:2010-08-16

摘要:

目的    评价异甘草酸镁治疗伴高胆红素血症病毒性肝炎的临床疗效。方法    将117例伴高胆红素血症病毒性肝炎患者随机分为两组,除普通治疗外,治疗组加用异甘草酸镁治疗,检测两组患者治疗前后血清生化学指标。结果    异甘草酸镁治疗伴高胆红素血症病毒性肝炎4周后,治疗组总有效率为82.5%,优于对照组的70.4%(P=0.004);随访4周后,治疗组总有效率为88.9%,明显优于对照组的53.7%(P<0.001)。异甘草酸镁具有抗肝纤维化作用且无明显不良反应。结论    异甘草酸镁可以有效治疗伴高胆红素血症的病毒性肝炎。

关键词: 异甘草酸镁;肝炎,病毒性;高胆红素血症;肝纤维化

Abstract:

Objective    To evaluate the clinical efficacy of magnesium isoglycyrrhizinate in the management of virus hepatitis with hyperbilirubinemia. Methods    117 patients with virus hepatitis with hyperbilirubinemia were randomly divided into the therapy group and the control group. Besides routine therapy, patients in the therapy group received management of magnesium isoglycyrrhizinate. The serum biochemical parameters were determined in all patients at the onset and end of treatment. Results    Four weeks after the treatment, the total effective response was 82.5% in the therapy group and 70.4% in the control group with a significant difference (P=0.004). After four week follow up, the total effective response was 88.9% in the therapy group and 53.7% in the control group with a significant difference (P<0.001). The treatment with magnesium isoglycyrrhizinate was effective in reducing liver fibrosis and without significant side effects. Conclusion    Magnesium isoglycyrrhizinate is effective for virus hepatitis with hyperbilirubinemia.

Key words: Magnesium isoglycyrrhizinate; Hepatitis, viral hepatitis; Hyperbilirubinemia; Liver fibrosis

中图分类号: 

  • R512.6
[1] 符晓莉,王磊,刘峰. 乙肝病毒感染不同阶段血清HBsAg定量值及其与HBV DNA水平和年龄的相关性[J]. 山东大学学报(医学版), 2013, 51(5): 94-98.
[2] 张秀珍,刘莉,刘倩. 慢性乙型肝炎患者血清瘦素水平与抗病毒治疗应答的相关性[J]. 山东大学学报(医学版), 2012, 50(9): 96-99.
[3] 孙超1,2, 解双双2, 肖迪2, 刘彩霞1,2, 于进红2, 刘莉2, 李强2. 急性乙型肝炎伴严重高胆红素血症的危险因素[J]. 山东大学学报(医学版), 2012, 50(8): 88-.
[4] 谭林,李莎莎,高学武. 抗病毒联合糖皮质激素和血浆置换早期干预肝衰竭倾向乙肝患者观察[J]. 山东大学学报(医学版), 2012, 50(3): 90-92.
[5] 崔海彬1,崔速南2,汪明明2,张秀珍2,刘葵花2,郭楠1. 血浆渗透压评分对肝肾综合征的预后评价[J]. 山东大学学报(医学版), 2011, 49(6): 103-106.
[6] 关彦彦1,姚永远1,王刚1,邵丽华2,赛林涛1,马立宪1. DMSO、地塞米松对于HBV感染HepCHLine-4细胞能力的影响[J]. 山东大学学报(医学版), 2010, 48(10): 65-.
[7] 李月荣1,2,韩增禄2,王磊1. 慢性乙型肝炎患者不同肝功能状况与胃黏膜病变的相关性[J]. 山东大学学报(医学版), 2010, 48(4): 94-97.
[8] . 现有乙型肝炎多表位疫苗在中国人群中的理论免疫效果评价[J]. 山东大学学报(医学版), 2009, 47(10): 114-117.
[9] . 基于GIS的中国人群乙肝多表位疫苗的预测[J]. 山东大学学报(医学版), 2009, 47(7): 125-132.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!